STOCK TITAN

Corvus Pharmaceuticals Inc - CRVS STOCK NEWS

Welcome to our dedicated news page for Corvus Pharmaceuticals (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Corvus Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Corvus Pharmaceuticals's position in the market.

Rhea-AI Summary
Corvus Pharmaceuticals, Inc. unveils next-gen ITK inhibitor candidates for precise T cell modulation in immunology indications. Preclinical data for soquelitinib program presented at Keystone Symposia. Next-gen candidates aim to enable more precise inhibition of Th1, Th2, and Th17 cell function. Various disease types targeted with refined chemical structures. Soquelitinib shows activity in six T cell-mediated inflammatory and immune diseases. Potential to treat atopic dermatitis, asthma, psoriasis, rheumatoid arthritis, and more.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
clinical trial
-
Rhea-AI Summary
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) has received Orphan Drug Designation from the FDA for its lead ITK inhibitor candidate, soquelitinib, for the treatment of T cell lymphoma. The company is set to initiate a Phase 3 registrational clinical trial for soquelitinib in patients with relapsed peripheral T cell lymphoma in the second quarter of 2024. The orphan drug status provides various benefits to the drug developer, including tax credits, exemptions from certain FDA fees, and seven years of post-approval marketing exclusivity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.75%
Tags
clinical trial
-
Rhea-AI Summary
Corvus Pharmaceuticals, Inc. (CRVS) appoints Jeffrey Arcara as Chief Business Officer, bringing over 30 years of experience in the biopharmaceutical industry. Arcara will lead corporate strategy, business development, and new product planning, strengthening Corvus' ITK programs. His extensive industry experience includes roles at Teva Pharmaceuticals, Neuromed, Wyeth, and InKine Pharmaceutical Company. Arcara holds an MBA from UCLA and a B.A. in Finance and Marketing from University of Wisconsin-Madison.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
management
Rhea-AI Summary
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) announces the passing of Edith P. Mitchell, M.D., a valued member of the Board of Directors. Dr. Mitchell had a distinguished career in healthcare and oncology, serving in various positions at Thomas Jefferson University and making significant contributions to cancer care and research. The Company extends its condolences to her family, colleagues, and community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
management
-
Rhea-AI Summary
Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company (NASDAQ: CRVS), announced new interim data from its Phase 1/1b clinical trial of soquelitinib in patients with relapsed peripheral T cell lymphoma. The data confirmed durable anti-tumor activity and supported the advancement of soquelitinib into a Phase 3 registrational clinical trial. The results showed progression free survival, duration of response, and overall survival rates that exceed current standard of care therapies for patients with relapsed PTCL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
CRVS: Corvus Pharmaceuticals Finalizes Protocol for Soquelitinib Phase 3 Clinical Trial in PTCL, New Data Accepted for ASH Annual Meeting, Positive Preclinical Data in Solid Tumors and Autoimmune Conditions
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
earnings
Rhea-AI Summary
Corvus Pharmaceuticals will present new interim data from its Phase 1/1b trial of soquelitinib in patients with relapsed peripheral T cell lymphoma (PTCL) at the 65th ASH Annual Meeting & Exposition. The presentation will take place on December 9, 2023, and will focus on the immune regulatory mechanism of the ITK inhibitor Soquelitinib in refractory T cell lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
conferences clinical trial
-
Rhea-AI Summary
Corvus Pharmaceuticals, Inc. has published preclinical data demonstrating the potential of ITK inhibition as a novel approach to treat T cell-mediated inflammatory and immune diseases. The data showed that soquelitinib, an ITK inhibitor, was effective in six disease models and inhibited the production of Th2 and Th17 cells, targeting cytokines such as IL-4, IL-5, IL-13, and IL-17. Corvus is currently conducting clinical trials for soquelitinib in oncology indications and developing next-generation molecules for inflammatory and immune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
clinical trial
-
Rhea-AI Summary
Corvus Pharmaceuticals, Inc. will host a conference call and webcast on November 7, 2023, at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2023 financial results. The conference call can be accessed by dialing 1-877-407-0784 (toll-free domestic) or 1-201-689-8560 (international) or via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.42%
Tags
earnings
Rhea-AI Summary
Corvus Pharmaceuticals plans to initiate a Phase 3 clinical trial for soquelitinib in Q1 2024, following a positive meeting with the FDA. The trial will enroll 150 patients with relapsed peripheral T cell lymphoma. The Company anticipates potential benefits in addressing a wide range of indications beyond hematologic cancers. The news is expected to positively impact the stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.53%
Tags
clinical trial
Corvus Pharmaceuticals Inc

Nasdaq:CRVS

CRVS Rankings

CRVS Stock Data

113.77M
34.40M
3.89%
40%
2.81%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Burlingame

About CRVS

corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.